Production Begins at Phillips-Medisize Production Site in Finland
Phillips-Medisize Corporation has announced the start of production and completion of the 6,000 m2 expansion to its Kontiolahti, Finland site. Production has already begun and will continue to ramp up on several new programmes before the first of the year. The site focuses on the industrialisation and production of inhalers, insulin pens, transfer devices and syringes.
The expansion includes 1,200 m2 of Class 8 cleanroom manufacturing and assembly and has space for the additional expansion for moulding machines and assembly. New, state-of-the art, high-speed automation lines enable the ramp up of multi-component, complex drug delivery devices from prototype to high-speed automated 24/7 mass production under competitive cost-structure. Total Kontiolahti numbers now include multiple, high-speed, fully automated assembly lines, fully automated printing lines and several semi-automated lines.
Since 1990, the Kontiolahti team has been serving the pharmaceutical industry with strong engineering resources, along with injection moulding and high-speed automation expertise to support complex, high volume programmes. The in-house tooling area, coupled with experts on the pre-production team, plays a vital role in the product development and industrialisation of the demanding drug delivery device projects.
Commenting on this plant expansion, Matt Jennings, President and CEO of Phillips-Medisize Corporation, stated: “The ISO 13485 multi-site QMS certified expansion brings our medical manufacturing square footage to over 1 million square feet (92,900 m2), with 270,000 square feet (25,000 m2) of cleanroom. This, coupled with extensive in-house tooling, state-of-the-art metrology, high-volume automated assembly capabilities, innovative technologies and creative people, upholds our mission to provide the highest level of satisfaction to our customers."
Phillips-Medisize Corporation, +1 715 381 3213, lori.feiten@phillipsmedisize.com, phillipsmedisize.com.